1 terminated. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Terminated 1 |
Follow Diffuse Large-cell B-cell Lymphoma: new trials by email Literature Review of Diffuse Large-cell B-cell Lymphoma trials Research Report on Diffuse Large-cell B-cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (R/R) Diffuse Large-cell B-cell Lymphoma (DLBCL) Plamotamab, Tafasitamab, Lenalidomide - Diffuse Large-cell B-cell Lymphoma | Phase 2 | Terminated | Xencor, Inc. | 3 | 2022-04-15 | 2024-04-30 |
Lymphoma, Large B-Cell, Diffuse (1) · Pyloric Stenosis, Hypertrophic (1)
Digestive System Diseases (1) · Gastric Outlet Obstruction (1) · Gastrointestinal Diseases (1) · Hemic and Lymphatic Diseases (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Lymphatic Diseases (1) · Lymphoma (1) · Lymphoma, B-Cell (1) · Lymphoma, Non-Hodgkin (1) · Lymphoproliferative Disorders (1) · Neoplasms (1) · Neoplasms by Histologic Type (1) · Pyloric Stenosis (1) · Stomach Diseases (1)
Lenalidomide (1) · tafasitamab (1)
Xencor, Inc. (1)
France (1) · Spain (1) · United States (1)